Literature DB >> 32019323

Treatment patterns in non-small-cell lung cancer in USA: results of the CancerMPact Survey 2018.

David Robinson1, Stephanie Hawthorne1, Linda Zhao1, Madelyn Hanson1, Gena Kanas1, Christine Davis1, Otavio Clark1.   

Abstract

Aim: To report the results of a survey of USA physicians (CancerMPact) that treat non-small-cell lung cancer patients. Materials & methods: 60 physicians were surveyed. Questions covered aspects of the treatment for all stages of the disease.
Results: For stage I patients, over 70% of the treatments were based on surgery. For stage II/III disease, a strong preference for combined therapy (surgery/radiation/systemic therapy) was observed. For advanced/stage IV patients, physicians used systemic therapy alone, and choosed the regimen based on histology and biomarkers. Use of PD-L1 inhibitors was highly dependent on histology and biomarkers.
Conclusion: The treatment choices of non-small-cell lung cancer are increasingly complex, involve different treatment modalities and are highly dependent on histology and biomarkers, besides stage.

Entities:  

Keywords:  chemotherapy; lung; non-small-cell lung cancer; patterns of care; survey

Mesh:

Substances:

Year:  2020        PMID: 32019323     DOI: 10.2217/fon-2019-0812

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  3 in total

Review 1.  A brief overview of thoracic surgery in the United States.

Authors:  Catherine T Byrd; Kiah M Williams; Leah M Backhus
Journal:  J Thorac Dis       Date:  2022-01       Impact factor: 3.005

2.  Treatment of HR+/HER2- breast cancer in urban mainland China: results from the CancerMPact Survey 2019.

Authors:  Bhavna Murali; Laura Durbin; Sapna Vijaykumar; Linda Yang; Song Li; Linda Zhao; Stephanie Hawthorne; Gena Kanas; Christine Davis; Otávio Clark
Journal:  Breast Cancer Res Treat       Date:  2022-08-20       Impact factor: 4.624

3.  MicroRNA-326 impairs chemotherapy resistance in non small cell lung cancer by suppressing histone deacetylase SIRT1-mediated HIF1α and elevating VEGFA.

Authors:  Jinying Wei; Guangping Meng; Jing Wu; Ying Wang; Qiang Zhang; Ting Dong; Jin Bao; Chunyan Wang; Jie Zhang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.